Ligelizumab is an IgE-directed monoclonal antibody under investigation for the treatment of chronic spontaneous urticaria (CSU). Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE).
- Mechanism
- Curator reviewed · 3 references
Immunoglobulin E (IgE) is a key driver of hypersensitivity reactions, and has thus become an attractive target in the treatment of immune-mediated hypersensitivity disorders. Immediate hypersensitivity reactions are due to IgE binding with FcεRI, which activates allergic effector cells that undergo degranulation to release vasoactive and pro-inflammatory mediators. IgE also binds to CD23/FcεRII, which appears responsible for antigen presentation, antigen transport across airway/epithelial barriers, and the regulation of IgE synthesis.
Ligelizumab is a monoclonal antibody directed at IgE, binding specifically to an epitope in the IgE Cε3 domain. It neutralizes serum IgE and also appears to inhibit the production of IgE via inhibition of IgE-FcεRI binding activity and, to a lesser extent, IgE binding to CD23.
- Code names
- QGE031
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with Ligelizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account